Clinical Trial Update: Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 study evaluating CE-224,535 taken twice daily for rheumatoid arthritis in patients not fully responsive to methotrexate; trial completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CE-224,535

Snippet

Sponsor: Pfizer | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: COMPLETED | Results posted: 2022-04-04